Intravenous rehydration in children with severe malnutrition and severe dehydration: a systematic review and meta-analysis.

Arch Dis ChildSep 18, 2026 (epub)
Clinical ResearchPediatricsGastroenterologyOpen access

Juan Emmanuel Dewez, San Maurice Ouattara, Temmy Sunyoto et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of intravenous rehydration (IVR) compared to oral rehydration (OR) in children with severe acute malnutrition (SAM) and severe dehydration. Conducted in lower-to-middle-income countries, the analysis included three RCTs with 484 participants. The pooled risk ratio for in-hospital mortality was 0.71, indicating a potential reduction in mortality with IVR.

Key findings

  • Pooled risk ratio for in-hospital mortality with IVR vs OR was 0.71 (95% CI 0.46 to 1.10).
  • No fluid overload events were reported, with a pooled risk ratio of 0.99 (95% CI 0.10 to 9.35).
  • Pooled risk ratio for severe hyponatraemia at 24 hours was 0.66 (95% CI 0.44 to 0.99).

Why it matters

Understanding the comparative effectiveness of IVR and OR in this vulnerable population is crucial for improving clinical outcomes and reducing mortality associated with severe dehydration in children with SAM.

Source

PubMed · PMID 42161576Free full text on PubMed Central

Published in Arch Dis Child. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.